Catalyst Pharmaceuticals (CPRX) Tops Q2 EPS by 29c ; Offers Guidance
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Price: $31.45 +0.03%
EPS Growth %: -30.9%
Financial Fact:
General and administrative: 1.42M
Today's EPS Names:
CRMT, More
EPS Growth %: -30.9%
Financial Fact:
General and administrative: 1.42M
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q2 EPS of $0.68, $0.29 better than the analyst estimate of $0.39. Revenue for the quarter came in at $146.54 million versus the consensus estimate of $140.22 million.
GUIDANCE:
Catalyst Pharmaceuticals sees FY2025 revenue of $545-565 million, versus the consensus of $560.7 million.
For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Trump: 40-60% of chip manufacturing will be in the U.S. - CNBC Interview
- RBC Capital Upgrades GEA Group AG (G1A:GR) (GEAGY) to Outperform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
